A Phase I study of STI-A1015 (IMC-001) in patients suffering from solid tumors

Trial Profile

A Phase I study of STI-A1015 (IMC-001) in patients suffering from solid tumors

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs STI-A1015 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Feb 2018 New trial record
    • 05 Feb 2018 According to a Sorrento Therapeutics media release, the company is planning to conduct Phase 1 studies at two clinical sites in South Korea, namely, Seoul National University Hospital (SNUH) and Samsung Medical Center (SMC).
    • 05 Feb 2018 According to a Sorrento Therapeutics media release, the South Korean Ministry of Food and Drug Safety (MFDS) has approved ImmuneOncia Therapeutics IND to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top